Vaccine and Infectious Disease and Clinical Research Divisions, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-4417, USA.
Hematology Am Soc Hematol Educ Program. 2011;2011:305-9. doi: 10.1182/asheducation-2011.1.305.
Although major progress has been made in the prevention of CMV disease after hematopoietic cell transplantation (HCT), specific problems remain and available antiviral agents are associated with major toxicities. This article reviews current aspects of CMV diagnosis, prevention, and treatment in HCT recipients and defines areas of unmet medical need.
尽管在造血细胞移植（HCT）后预防 CMV 疾病方面已经取得了重大进展，但仍存在一些具体问题，而且现有的抗病毒药物都伴随着严重的毒性。本文回顾了 HCT 受者中 CMV 的诊断、预防和治疗的现状，并确定了未满足医疗需求的领域。
